BioMed Research International

BioMed Research International / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 4374087 | 8 pages | https://doi.org/10.1155/2018/4374087

Lutein and Zeaxanthin Isomers Reduce Photoreceptor Degeneration in the Pde6brd10 Mouse Model of Retinitis Pigmentosa

Academic Editor: Mitsuru Nakazawa
Received02 Oct 2018
Accepted29 Nov 2018
Published17 Dec 2018

Abstract

Purpose. Lutein, RR-zeaxanthin, and RS-zeaxanthin (L-Z) are antioxidants which can reduce endoplasmic reticulum stress (ERS) and oxidative stress (OS), and ameliorate neurodegenerative diseases. However, their treatment effect in the Pde6brd10 (rd10) mouse model of retinitis pigmentosa (RP) and the underlying cellular mechanisms have not been studied. ERS is an important factor which causes photoreceptor apoptosis. The aim of the current project is to test the treatment effect of L-Z in rd10 mice and to investigate the underlying molecular mechanisms of ERS. Methods. L-Z (Lutemax 2020, 10 mg/kg) diluted in sunflower oil (SFO, 1 mg/ml) or the same volume of SFO was administrated via gavage from postnatal day 6 (P6) to P20 daily in L-Z group (n=5) or SFO group (n=6) of rd10 mice. At P21, electroretinography (ERG) was performed to show the functional change of retinas. 78 kDa glucose-regulated protein (GRP78) and endoplasmic reticulum protein 29 (ERp29) were tested by western blot and immunostaining. Results. The ERG amplitudes were larger in the L-Z group than those of the SFO group in all flash luminances of dark-adapted and light-adapted ERG (all p < 0.01). Western blot revealed that GRP78 in the retinas of the L-Z group was significantly downregulated compared to that of the SFO group (p < 0.01). Meanwhile, the retinal ERp29 protein was significantly upregulated in the L-Z treatment group than that of the SFO group (p < 0.01). Conclusions. L-Z provide protection to the photoreceptors of rd10 mouse model of RP, which is probably associated with the reduction of ERS.

1. Introduction

Retinitis pigmentosa (RP) is an inherited retinal degenerative disease which affects one in 3500-5000 individuals [1]. The common clinical symptoms of RP include night blindness and progressive vision loss from peripheral to central vision due to the degeneration of rod and cone photoreceptors, which could eventually lead to irreversible blindness [2]. However, the exact pathologic mechanism of the photoreceptor death has not been fully understood. It was found that the death of cone as well as rod may be due to OS [3] and ERS [4]. As RP is a kind of disease resulting from mutant genes, increasing knowledge of the causative genes with the associated biochemical pathogenesis have been gained, and gene therapy has emerged as one of the most potential treatments for RP [5, 6]. Recently, the U.S. Food and Drug Administration has approved the first gene therapy for a type of RP, Leber congenital amaurosis, which is caused by a mutant RPE65 gene [7, 8]. However, RP is highly genetically heterogeneous with over 200 mutations linked to more than 60 human genes [9, 10]. Until now, it is still not feasible to correct all RP mutations. Therefore, it is necessary to study pharmacological intervention that targets the common and major cellular signaling pathways of the pathogenesis of RP to control retinal degeneration [11].

Although RP is genetically heterogeneous, apoptosis is widely recognized as the general final pathway for the death of photoreceptors [12]. ERS, caused by excessive misfolded proteins in the ER, could activate the ER unfolded protein response (UPR) and the apoptotic pathways [1315], which has been associated with neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease [16, 17]. These diseases cause the accumulation of misfolded proteins and ERS, which could eventually lead to the apoptosis of neuronal cells [18]. In addition, a lot of studies provide evidence that ERS is present in many types of photoreceptor degenerations, such as light-induced retinopathy [19], experimental retinal detachment [20], achromatopsia, and RP [21]. In addition, the interventions that ameliorate ERS render protection to photoreceptors and reduce the rate of photoreceptor death [22].

L-Z, the two major xanthophylls, are the oxygenated forms of carotenoids [23] that are usually accumulated in the central retina of human eyes [24], with the protective effect in human and animal models of retinal degeneration [2531]. However, the mechanism of L-Z in RP has not been clearly elucidated. The main mechanism of the protective effect of L-Z is attributed to the antioxidant ability [32, 33], while the reduction of ERS might be another related mechanism. We previously showed that L-Z ameliorated the ERS in the protection against light-induced retinopathy [34]. The rd10 mouse is a RP model with clear characteristics [3538], which carries a missense point mutation in exon 13 of the rod phosphodiesterase 6B (Pde6b) gene [36, 37]. The mutations in the same gene also cause human RP [39, 40]. In the present study, the protective effect of L-Z on the retinas of rd10 mice was investigated. Furthermore, the involvement of ERS was also explored to explain the protective effect of L-Z on the retinal degeneration of rd10 retinas.

2. Materials and Methods

2.1. Animals and Experimental Design

The breeding pairs of rd10 mice (Stock Number: 004297) were purchased from the Jackson Laboratory (Bar Harbor, ME). All animal procedures were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic Foundation and were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.

L-Z (Lutemax 2020, 10 mg/kg of body weight, OmniActive Health Technologies, Mumbai, India) dissolved in SFO (1 mg/ml, W530285, Sigma, St. Louis, MO) or the same volume of SFO was administered by daily oral gavage from P6 to P20 to rd10 mice in L-Z treatment group (n=5) or SFO group (n=6), respectively. This dose of L-Z was used based on our preliminary data of different doses (data not shown), which is the highest dose without significant adverse effect on the growth of body weight. The mice in each litter were randomly assigned to the L-Z group and the SFO group. At P21, ERG was performed to show the change of retinal function. The order of the mice in the same litter for ERG test was random. 78 kDa glucose-regulated protein (GRP78) and endoplasmic reticulum protein 29 (ERp29) were tested by western blot and immunostaining. The number of the animals used was conservative enough for obtaining the statistical power of 0.8 or higher.

2.2. Electroretinography (ERG)

Before ERG test, the mice were taken out from a cabinet in which the mice were kept for overnight dark adaptation, and were anesthetized with ketamine (80 mg/kg) and xylazine (16 mg/kg) dissolved in saline solution. The pupils were dilated with 1% cyclopentolate HCl, 2.5% phenylephrine HCl, and 1% tropicamide. The corneal surface was anesthetized with 0.5% proparacaine HCl. During the ERG test, the mouse was placed onto a platform with a heating pad in a grounded Faraday cage to keep the body temperature of the anesthetized mouse at 37°C and to reduce electromagnetic interference. The amplitudes of a-wave and b-wave were tested in a series of flash luminances to obtain the luminance-response functions of dark-adapted and light-adapted ERG. In dark-adapted session of ERG test, the flash luminance ranged from -3.6 to 2.1 log cd s/m2. In light-adapted session of ERG test, the flash luminance ranged from -0.8 to 1.9 log cd s/m2. The light-adaptation time was 7 minutes before the first light-adapted ERG was recorded. The a-wave and b-wave amplitudes were used for the evaluation of the retinal function. The a-wave amplitude was measured from the baseline to the amplitude at 8 ms after the onset of flash stimulation. The b-wave amplitude was measured from the a-wave trough to the b-wave peak, using the published procedure [34, 4146].

2.3. Western Blotting

The same protocol in our previous study [34] was used. Briefly, the retinas were extracted from mouse eyeballs with a cut on the cornea, and were homogenized. The proteins were obtained in the supernatant after centrifugation of the lysates at 16,000 x g for 25 minutes at 4°C and measured by Pierce 660 nm Protein Assay Reagent (Thermo Scientific, Rockford, IL). Equal amounts of protein (15 μg) of each extract in Laemmli Sample buffer were heated for 7 minutes and then electrophoresed on 8-16% gradient sodium dodecyl sulfate- (SDS-) polyacrylamide gel. Afterwards, the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked and then incubated with primary antibodies (anti-GRP78/BiP, 1:300, ab21685 and anti-ERp29, 1:2500, ab11420, Abcam, Cambridge, MA) in Tris buffered saline with Tween 20 (TBST) for 16 hours at 4°C. After washing 3 times with TBST, the membrane was incubated with secondary antibody goat-anti-rabbit Immunoglobulin G- (IgG-) horseradish peroxidase (HRP) (1:7000, sc-2004, Santa Cruz, CA) in TBST for 1 hour at 25°C. The membrane was then washed 3 times with TBST. Finally, the antigen-antibody complexes were detected by the enhanced chemilu minescence-2 (ECL-2, Thermo Scientific, Rockford, CA).

2.4. Immunostaining

The eyeballs were harvested and fixed in 4% paraformaldehyde (PFA) with 1X phosphate buffer saline (PBS, pH 7.4) for 20 minutes and then a hole was punched on the cornea. The eyes were put back to the 4% PFA fixative for additional 4 hours. Afterwards, the eyeballs were immersed in three graded sucrose solutions in 1X PBS in the following order/time: 10% for 1 hour, 20% for 1 hour, and 30% overnight. The eyeballs were then embedded in optimum temperature cutting compound (OCT), flash frozen on dry ice, and stored in −80°C freezer for at least overnight. The eyeballs in OCT were sectioned with a cryostat (Leica CM 1850, Buffalo Grove, IL) to 8 micron sections. Protein expression in situ was tested by immunofluorescence staining. The sections were incubated in 1X PBS containing 5% normal goat serum, 1% bovine serum albumin (BSA), and 0.5% Triton X-100 for 1 hour to block nonspecific binding, followed by incubation with primary antibodies (anti-GRP78/BiP, 1:400, ab21685 and anti-ERp29, 1:500, ab11420, Abcam, Cambridge, MA) overnight at 4°C. After three washes with 1X PBS, the sections of retinas were incubated with secondary antibody goat anti-rabbit IgG H&L Alexa Fluo® 555 (1:600, ab150086, Abcam, Cambridge, MA) for 2 hours at room temperature. After washing with 1X PBS, sections were mounted with VECTASHIELD mounting medium with 4′,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA) and examined under a fluorescent microscope (BX61, Olympus, Tokyo, Japan).

2.5. Measurement of ONL Thickness

The DAPI-stained images obtained in the above procedure were used for the measurement of the thickness of outer nuclear layer (ONL). The locations for the measurement of ONL thickness were at 200 μm from the edges of the optic disc on both sides of the optic nerve head. ImageJ 1.48v software (National Institutes of Health, Bethesda, MD) was used for the measurement. In each retina, four sections were used to obtain the average of ONL thickness.

2.6. Statistical Analysis

For the analysis of ERG data, two-way repeated measures analysis of variance (ANOVA) was performed. For the analysis of the other data, one-way ANOVA was performed.

3. Results

3.1. The Effect of L-Z on Retinal Function of rd10 Mice

The retinal function of mice was tested by ERG (Figure 1). The ERG waveform typically consists of a-wave followed by b-wave. In dark-adapted ERG, the a-wave is the response from rod or rod/cone photoreceptors, and the b-wave is mainly from bipolar cells of the rod or rod/cone pathways, which is also affected by the output of rod or rod/cone photoreceptors. The b-wave of the light-adapted ERG is from bipolar cells of the cone pathway, which is also affected by the output of cone photoreceptors. Our ERG data showed that the a-wave and b-wave amplitudes of the dark-adapted ERG were significantly larger in the L-Z treatment group than those in the SFO group under the flash luminances we used (all p < 0.01). In addition, the b-wave amplitudes of the light-adapted ERG of the L-Z treatment group were significantly higher than those in the SFO group under all of the flash luminances tested (all p < 0.01).

3.2. The Effect of L-Z on ERS in rd10 Mice

GRP78 acts as the main ER chaperon of the UPR, while the role of ERp29 has not been clearly elucidated in ERS. They were tested by western blot and immunostaining in this study. Our western blot data (Figure 2) revealed that GRP78 in the retina of the L-Z treatment group was significantly downregulated compared to that in the SFO group (p < 0.01). Meanwhile, the retinal ERp29 was significantly upregulated in the L-Z treatment group than that of the SFO group (p < 0.01).

Immunostaining of GRP78 showed that GRP78 protein was expressed mainly in the inner segment (IS), inner nuclear layer (INL), outer plexiform layer (OPL) and ganglion cell layer (GCL) in the SFO group. This result is consistent with the finding of another study [47] and our previous studies [34, 41, 42]. On the other hand, there was a marked downregulation of GRP78 in the above retinal layers in the L-Z treatment group compared to the SFO group (Figure 3). The immunostaining of ERp29 revealed that there was a weak expression of ERp29 presented only in the GCL of the SFO group. However, ERp29 expression was upregulated in IS, OPL, INL and GCL in the retina of the L-Z group compared to the SFO group (Figure 3).

3.3. The Effect of L-Z on ONL Thickness in rd10 Mice

The ONL thickness (mean ± SD) was measured in the DAPI staining of immunostaining images, which showed significant increase of ONL thickness in the L-Z group than in the SFO group (p < 0.01).

4. Discussion

The present study revealed the protective effect of L-Z on photoreceptor degeneration of rd10 mice, an animal model of retinitis pigmentosa. The ERG results in our study showed that L-Z treatment improved rod and cone functions in rd10 mice, rendering protective effect on both rod and cone photoreceptors.

rd10 mice have long been established as an animal model of RP in several studies. It was observed that at 2 weeks of age, the photoreceptors of rd10 mice already show minor photoreceptor degeneration [48]. By 8 weeks of age, most of the photoreceptors disappear [49]. The progressive photoreceptor degeneration in this strain of mice is attributed to a homozygous point mutation in Pde6b gene [36, 37]. Some mutations in Pde6b gene have also been found in human RP patients [50, 51]. The photoreceptor degeneration in rd10 mice leads to deterioration of the retinal function. The a-wave and b-wave of ERG are still detectable at 3-week-old mice, but these components are not recordable at the age of 5 weeks [52].

The antioxidants used for the treatment in this study are L-Z, which can neutralize reactive oxygen species to counter oxidative damage in retinal cells in many eye disorders [23, 5356]. In addition, our previous study showed that L-Z reduce ERS in light-induced retinopathy [34].

Endoplasmic reticulum (ER) is the organelle for protein folding and assembly. When the cellular homeostasis is interfered, the protein misfolding or unfolding induces ERS and activates the UPR, which can reduce ERS by increasing ER protein folding capacity, increasing degradation of misfolded proteins, and suppressing the translation of proteins. However, under persistent ERS, the UPR signaling can cause cell death by activating the intrinsic pathway of apoptosis [5761]. ERS is associated with many retinal diseases, including RP. The amelioration of ERS can reduce photoreceptor degeneration in rd10 mice [41, 42, 62, 63]. In this study, our result illustrated that administration of L-Z reduced the ERS, which was indicated by the downregulation of GRP78, a marker of ERS [6466].

While our GRP78 test verified that L-Z reduced the ERS, we are also interested in the expression of endoplasmic reticulum protein 29 (ERp29) which was investigated in recent retinal studies [67, 68]. ERp29, ubiquitously expressed in the ER membrane among various tissues and cell types, is an ER luminal protein in all mammals [69, 70]. It plays a pivotal role in modulating the folding and transportation of proteins during ERS [67]. GRP78 is one of the main targets of ERp29 [69]. In addition, ERp29 could also regulate other proteins, such as p38, and heat shock protein 27 (Hsp27), for cell survival or apoptosis during ERS [71, 72].

According to previous studies, the change of ERp29 level has at least two phases of either upregulation or downregulation during ERS [68, 73]. Zhang et al. reported that ERp29 expression is beneficial to cellular viability. Overexpression of ERp29 in ARPE-19 cell line with cigarette smoke extract- (CSE-) triggered ERS reduced the number of apoptotic cells, while the inhibition of ERp29 upregulated CSE-triggered CCAAT/enhancer-binding protein homologous protein (CHOP) expression and induced cell apoptosis [68]. The ERS induced by 6-hour, 24-hour and 10-day CSE administration upregulated ERp29. However, during 3-week CSE administration, the expression of ERp29 was downregulated while the GRP78 was still upregulated. Furthermore, a peak level of ERp29 expression was induced by a medium level of CSE in their study [68]. In the study of Park et al., ERp29 was downregulated 1 day after spinal injury and upregulated around 7 days after spinal injury [73]. Therefore, it is possible that the direction of the change of ERp29 level is associated with the level or duration of ERS. In our study, ERp29 was upregulated while the GRP78 was downregulated after the L-Z treatment, which implies that ERp29 may reduce ERS and protect retinal cells. Our result of the SFO group is consistent with the result in the 3-week CSE-induced ERS experiment of Zhang et al. [68]. In the SFO group of rd10 retinas, it is possible that there is long-term ERS. It is not surprising that the high level of GRP78 and the low level of ERp29 were shown in this group. After L-Z treatment, the oxidative stress was reduced in the rd10 retinas, which reduced the ERS indicated by the reduction of GRP78 level [7478]. In the meantime, the ERp29 level was increased due to the change of ERS level, which in turn downregulated the expression of GRP78 and finally reduced the photoreceptor apoptosis.

5. Conclusions

In conclusion, L-Z prevent photoreceptors from degeneration in rd10 retinas, which is possibly associated with the reduction of ERS. Future studies are necessary to clarify the details of the cellular pathways in which L-Z provide the protective effect against retinal degeneration. Our study reveals the possible target of ERS in photoreceptors for the treatment of retinal degenerations.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Minzhong Yu was in charge of the project conception, designing the experiments, applying for the main research grant, organizing and supervising the project, performing of some of the experiments, analyzing and interpreting all of the data, drafting and revising the manuscript. Weiming Yan interpreted all of the data, drafted and revised the manuscript. Craig Beight performed some of the experiments.

Acknowledgments

This research was funded by OmniActive Health Technologies Ltd., India Research Grant, NIH P30EY025585 and Research to Prevent Blindness. In addition, we would like to thank Professor Zuoming Zhang, the Fourth Military Medical University, Xi’an, China, for sending Weiming Yan, who is now a resident in the Department of Ophthalmology, Fuzhou General Hospital of Chinese PLA, to Cleveland Clinic Foundation to participate in this work.

References

  1. S. P. Daiger, L. S. Sullivan, and S. J. Bowne, “Genes and mutations causing retinitis pigmentosa,” Clinical Genetics, vol. 84, no. 2, pp. 132–141, 2013. View at: Publisher Site | Google Scholar
  2. S. K. Verbakel, R. A. van Huet, C. J. Boon et al., “Non-syndromic retinitis pigmentosa,” Progress in Retinal and Eye Research, vol. 66, pp. 157–186, 2018. View at: Publisher Site | Google Scholar
  3. K. Komeima, B. S. Rogers, L. Lu, and P. A. Campochiaro, “Antioxidants reduce cone cell death in a model of retinitis pigmentosa,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 103, no. 30, pp. 11300–11305, 2006. View at: Publisher Site | Google Scholar
  4. A. Griciuc, L. Aron, and M. Ueffing, “ER stress in retinal degeneration: A target for rational therapy?” Trends in Molecular Medicine, vol. 17, no. 8, pp. 442–451, 2011. View at: Publisher Site | Google Scholar
  5. C. Schön, V. Sothilingam, R. Mühlfriedel et al., “Gene Therapy Successfully Delays Degeneration in a Mouse Model of PDE6A-Linked Retinitis Pigmentosa (RP43),” Human Gene Therapy, vol. 28, no. 12, pp. 1180–1188, 2017. View at: Publisher Site | Google Scholar
  6. M. F. Dias, K. Joo, J. A. Kemp et al., “Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives,” Progress in Retinal and Eye Research, vol. 63, pp. 107–131, 2018. View at: Publisher Site | Google Scholar
  7. B. Takkar, P. Bansal, and P. Venkatesh, “Leber’s Congenital Amaurosis and Gene Therapy,” The Indian Journal of Pediatrics, vol. 85, no. 3, pp. 237–242, 2018. View at: Publisher Site | Google Scholar
  8. N. Kumaran, M. Michaelides, A. J. Smith, R. R. Ali, and J. W. Bainbridge, “Retinal gene therapy,” British Medical Bulletin, vol. 126, no. 1, pp. 13–25, 2018. View at: Publisher Site | Google Scholar
  9. M. U. Ali, M. S. U. Rahman, J. Cao, and P. X. Yuan, “Genetic characterization and disease mechanism of retinitis pigmentosa; current scenario,” 3 Biotech, vol. 7, no. 4, 2017. View at: Google Scholar
  10. D. A. Simpson, G. R. Clark, S. Alexander, G. Silvestri, and C. E. Willoughby, “Molecular diagnosis for heterogeneous genetic diseases with targeted high-throughput DNA sequencing applied to retinitis pigmentosa,” Journal of Medical Genetics, vol. 48, no. 3, pp. 145–151, 2011. View at: Publisher Site | Google Scholar
  11. H. Yang, Y. Fu, X. Liu et al., “Role of the sigma-1 receptor chaperone in rod and cone photoreceptor degenerations in a mouse model of retinitis pigmentosa,” Molecular Neurodegeneration, vol. 12, no. 1, 2017. View at: Publisher Site | Google Scholar
  12. S. Cottet and D. F. Schorderet, “Mechanisms of apoptosis in retinitis pigmentosa,” Current Molecular Medicine, vol. 9, no. 3, pp. 375–383, 2009. View at: Publisher Site | Google Scholar
  13. R. Sano and J. C. Reed, “ER stress-induced cell death mechanisms,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1833, no. 12, pp. 3460–3470, 2013. View at: Publisher Site | Google Scholar
  14. N. Sovolyova, S. Healy, A. Samali, and S. E. Logue, “Stressed to death - Mechanisms of ER stress-induced cell death,” biological chemistry, vol. 395, no. 1, pp. 1–13, 2014. View at: Publisher Site | Google Scholar
  15. E. Szegezdi, S. E. Logue, A. M. Gorman, and A. Samali, “Mediators of endoplasmic reticulum stress-induced apoptosis,” EMBO Reports, vol. 7, no. 9, pp. 880–885, 2006. View at: Publisher Site | Google Scholar
  16. T. Xu, Y. Zhang, J. He et al., “Bajijiasu Ameliorates β-Amyloid-Triggered Endoplasmic Reticulum Stress and Related Pathologies in an Alzheimer’s Disease Model,” Cellular Physiology and Biochemistry, vol. 46, no. 1, pp. 107–117, 2018. View at: Publisher Site | Google Scholar
  17. X.-S. Zeng, J.-J. Jia, Y. Kwon, S.-D. Wang, and J. Bai, “The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease,” Free Radical Biology & Medicine, vol. 67, pp. 10–18, 2014. View at: Publisher Site | Google Scholar
  18. Y. Cai, J. Arikkath, L. Yang, M. Guo, P. Periyasamy, and S. Buch, “Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders,” Autophagy, vol. 12, no. 2, pp. 225–244, 2016. View at: Publisher Site | Google Scholar
  19. M. Shimazawa, S. Sugitani, Y. Inoue, K. Tsuruma, and H. Hara, “Effect of a sigma-1 receptor agonist, cutamesine dihydrochloride (SA4503), on photoreceptor cell death against light-induced damage,” Experimental Eye Research, vol. 132, pp. 64–72, 2015. View at: Publisher Site | Google Scholar
  20. Q. Yan, H. Zhu, F.-H. Wang et al., “Inhibition of TRB3 Protects Photoreceptors against Endoplasmic Reticulum Stress-Induced Apoptosis after Experimental Retinal Detachment,” Current Eye Research, vol. 41, no. 2, pp. 240–248, 2016. View at: Publisher Site | Google Scholar
  21. P. Chan, J. Stolz, S. Kohl, W.-C. Chiang, and J. H. Lin, “Endoplasmic reticulum stress in human photoreceptor diseases,” Brain Research, vol. 1648, pp. 538–541, 2016. View at: Publisher Site | Google Scholar
  22. Y. Shirai, A. Mori, T. Nakahara, K. Sakamoto, and K. Ishii, “Deferiprone Protects against Photoreceptor Degeneration Induced by Tunicamycin in the Rat Retina,” Biological & Pharmaceutical Bulletin, vol. 38, no. 7, pp. 1076–1080, 2015. View at: Publisher Site | Google Scholar
  23. Y.-P. Jia, L. Sun, H.-S. Yu et al., “The pharmacological effects of lutein and zeaxanthin on visual disorders and cognition diseases,” Molecules, vol. 22, no. 4, article no. 610, 2017. View at: Publisher Site | Google Scholar
  24. R. Vishwanathan, W. Schalch, and E. J. Johnson, “Macular pigment carotenoids in the retina and occipital cortex are related in humans,” Nutritional Neuroscience, vol. 19, no. 3, pp. 95–101, 2016. View at: Publisher Site | Google Scholar
  25. M. Mozaffarieh, S. Sacu, and A. Wedrich, “The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence,” Nutrition Journal , vol. 2, article 20, 2003. View at: Publisher Site | Google Scholar
  26. B. Li, G. T. Rognon, T. Mattinson et al., “Supplementation with macular carotenoids improves visual performance of transgenic mice,” Archives of Biochemistry and Biophysics, vol. 649, pp. 22–28, 2018. View at: Publisher Site | Google Scholar
  27. M. Miranda, E. Arnal, S. Ahuja et al., “Antioxidants rescue photoreceptors in rd1 mice: relationship with thiol metabolism,” Free Radical Biology & Medicine, vol. 48, no. 2, pp. 216–222, 2010. View at: Publisher Site | Google Scholar
  28. S. R. Kim, K. Nakanishi, Y. Itagaki, and J. R. Sparrow, “Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin,” Experimental Eye Research, vol. 82, no. 5, pp. 828–839, 2006. View at: Publisher Site | Google Scholar
  29. E. L. Berson, B. Rosner, M. A. Sandberg et al., “Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A,” JAMA Ophtalmology, vol. 128, no. 4, pp. 403–411, 2010. View at: Publisher Site | Google Scholar
  30. N. K. Scripsema, D.-N. Hu, and R. B. Rosen, “Lutein, Zeaxanthin, and meso-Zeaxanthin in the Clinical Management of Eye Disease,” Journal of Ophthalmology, vol. 2015, Article ID 865179, 2015. View at: Google Scholar
  31. C. Mewborn, C. Lindbergh, T. Robinson et al., “Lutein and Zeaxanthin Are Positively Associated with Visual–Spatial Functioning in Older Adults: An fMRI Study,” Nutrients, vol. 10, no. 4, p. 458, 2018. View at: Publisher Site | Google Scholar
  32. P. Palombo, G. Fabrizi, V. Ruocco et al., “Beneficial long-term effects of combined oral/topical antioxidant treatment with the carotenoids lutein and zeaxanthin on human skin: A double-blind, placebo-controlled study,” Skin Pharmacology and Physiology, vol. 20, no. 4, pp. 199–210, 2007. View at: Publisher Site | Google Scholar
  33. A. Shinojima, M. Sawa, T. Sekiryu et al., “A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy,” Ophthalmologica, vol. 237, no. 3, pp. 159–166, 2017. View at: Publisher Site | Google Scholar
  34. M. Yu, W. Yan, and C. Beight, “Lutein and Zeaxanthin Isomers Protect against Light-Induced Retinopathy via Decreasing Oxidative and Endoplasmic Reticulum Stress in BALB/cJ Mice,” Nutrients, vol. 10, no. 7, p. 842, 2018. View at: Publisher Site | Google Scholar
  35. C. Gargini, E. Terzibasi, F. Mazzoni, and E. Strettoi, “Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study,” Journal of Comparative Neurology, vol. 500, no. 2, pp. 222–238, 2007. View at: Publisher Site | Google Scholar
  36. B. Chang, N. Hawes, M. Pardue et al., “Two mouse retinal degenerations caused by missense mutations in the β-subunit of rod cGMP phosphodiesterase gene,” Vision Research, vol. 47, no. 5, pp. 624–633, 2007. View at: Publisher Site | Google Scholar
  37. B. Chang, N. L. Hawes, R. E. Hurd, M. T. Davisson, S. Nusinowitz, and J. R. Heckenlively, “Retinal degeneration mutants in the mouse,” Vision Research, vol. 42, no. 4, pp. 517–525, 2002. View at: Publisher Site | Google Scholar
  38. C. R. Starr, P. M. Pitale, and M. Gorbatyuk, “Translational attenuation and retinal degeneration in mice with an active integrated stress response,” Cell Death & Disease, vol. 9, no. 5, 2018. View at: Publisher Site | Google Scholar
  39. M. E. McLaughlin, M. A. Sandberg, E. L. Berson, and T. P. Dryja, “Recessive mutations in the gene encoding the β–subunit of rod phosphodiesterase in patients with retinitis pigmentosa,” Nature Genetics, vol. 4, no. 2, pp. 130–134, 1993. View at: Publisher Site | Google Scholar
  40. M. E. McLaughlin, T. L. Ehrhart, E. L. Berson, and T. P. Dryja, “Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa.,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 92, no. 8, pp. 3249–3253, 1995. View at: Publisher Site | Google Scholar
  41. K. Kang, M. J. Tarchick, X. Yu, C. Beight, P. Bu, and M. Yu, “Carnosic acid slows photoreceptor degeneration in the Pde6b rd10 mouse model of retinitis pigmentosa,” Scientific Reports, vol. 6, no. 1, 2016. View at: Publisher Site | Google Scholar
  42. K. Kang and M. Yu, “Protective effect of sulforaphane against retinal degeneration in the Pde6rd10 mouse model of retinitis pigmentosa,” Current Eye Research, vol. 42, no. 12, pp. 1684–1688, 2017. View at: Publisher Site | Google Scholar
  43. M. Yu, K. Kang, P. Bu et al., “Deficiency of CC chemokine ligand 2 and decay-accelerating factor causes retinal degeneration in mice,” Experimental Eye Research, vol. 138, pp. 126–133, 2015. View at: Publisher Site | Google Scholar
  44. M. Yu, W. Zou, N. S. Peachey, T. M. McIntyre, and J. Liu, “A novel role of complement in retinal degeneration,” Investigative Ophthalmology & Visual Science, vol. 53, no. 12, pp. 7684–7692, 2012. View at: Publisher Site | Google Scholar
  45. M. Yu, G. Sturgill-Short, P. Ganapathy, A. Tawfik, N. S. Peachey, and S. B. Smith, “Age-related changes in visual function in cystathionine-beta-synthase mutant mice, a model of hyperhomocysteinemia,” Experimental Eye Research, vol. 96, no. 1, pp. 124–131, 2012. View at: Publisher Site | Google Scholar
  46. M. Yu, S. P. Narayanan, F. Wang, E. Morse, W. B. MacKlin, and N. S. Peachey, “Visual abnormalities associated with enhanced optic nerve myelination,” Brain Research, vol. 1374, pp. 36–42, 2011. View at: Publisher Site | Google Scholar
  47. S. Nookala, R. Gandrakota, A. Wohabrebbi et al., “In search of the identity of the XAP-1 antigen: A protein localized to cone outer segments,” Investigative Ophthalmology & Visual Science, vol. 51, no. 5, pp. 2736–2743, 2010. View at: Publisher Site | Google Scholar
  48. M. E. Pennesi, K. V. Michaels, S. S. Magee et al., “Long-term characterization of retinal degeneration in rd1 and rd10 mice using spectral domain optical coherence tomography,” Investigative Ophthalmology & Visual Science, vol. 53, no. 8, pp. 4644–4656, 2012. View at: Publisher Site | Google Scholar
  49. S. A. Jae, K. N. Ahn, J. Y. Kim, J. H. Seo, H. K. Kim, and Y. S. Goo, “Electrophysiological and Histologic Evaluation of the Time Course of Retinal Degeneration in the,” The Korean Journal of Physiology & Pharmacology, vol. 17, no. 3, p. 229, 2013. View at: Publisher Site | Google Scholar
  50. S. Shen, T. Sujirakul, and S. H. Tsang, “Next-generation sequencing revealed a novel mutation in the gene encoding the beta subunit of rod phosphodiesterase,” Ophthalmic Genetics, vol. 35, no. 3, pp. 142–150, 2014. View at: Publisher Site | Google Scholar
  51. “Novel mutations in PDE6B causing human retinitis pigmentosa,” International Journal of Ophthalmology, 2016. View at: Publisher Site | Google Scholar
  52. Sarah Rösch, Sandra Johnen, Frank Müller, Christiane Pfarrer, and Peter Walter, “Correlations between ERG, OCT, and Anatomical Findings in the rd10 Mouse,” Journal of Ophthalmology, vol. 2014, Article ID 874751, 10 pages, 2014. View at: Publisher Site | Google Scholar
  53. R. Arunkumar, C. M. Calvo, C. D. Conrady, and P. S. Bernstein, “What do we know about the macular pigment in AMD: the past, the present, and the future,” Eye (Basingstoke), pp. 1–13, 2018. View at: Google Scholar
  54. B. Rinsky, “Characterizing the effect of supplements on the phenotype of cultured macrophages from patients with age-related macular degeneration,” Mol Vis, vol. 23, pp. 889–899, 2017. View at: Google Scholar
  55. R. Yanai, S. Chen, S. Uchi et al., “Attenuation of choroidal neovascularization by dietary intake of ω-3 long-chain polyunsaturated fatty acids and lutein in mice,” PLoS ONE, vol. 13, no. 4, p. e0196037, 2018. View at: Publisher Site | Google Scholar
  56. K. Neelam, C. J. Goenadi, K. Lun, C. C. Yip, and K.-G. Au Eong, “Putative protective role of lutein and zeaxanthin in diabetic retinopathy,” British Journal of Ophthalmology, vol. 101, no. 5, pp. 551–558, 2017. View at: Publisher Site | Google Scholar
  57. H. Kroeger, W. Chiang, J. Felden, A. Nguyen, and J. H. Lin, “ER stress and unfolded protein response in ocular health and disease,” FEBS Journal. View at: Publisher Site | Google Scholar
  58. A. Shaheen, “Effect of the unfolded protein response on ER protein export: a potential new mechanism to relieve ER stress,” Cell Stress and Chaperones, vol. 23, no. 5, pp. 797–806, 2018. View at: Publisher Site | Google Scholar
  59. A. Saito and K. Imaizumi, “The broad spectrum of signaling pathways regulated by unfolded protein response in neuronal homeostasis,” Neurochemistry International, 2017. View at: Google Scholar
  60. S. X. Zhang, E. Sanders, S. J. Fliesler, and J. J. Wang, “Endoplasmic reticulum stress and the unfolded protein responses in retinal degeneration,” Experimental Eye Research, vol. 125, pp. 30–40, 2014. View at: Publisher Site | Google Scholar
  61. G. Jing, J. J. Wang, and S. X. Zhang, “ER Stress and Apoptosis: A New Mechanism for Retinal Cell Death,” Journal of Diabetes Research, vol. 2012, Article ID 589589, 11 pages, 2012. View at: Publisher Site | Google Scholar
  62. H. Osada, T. Okamoto, H. Kawashima et al., “Neuroprotective effect of bilberry extract in a murine model of photo-stressed retina,” PLoS ONE, vol. 12, no. 6, p. e0178627, 2017. View at: Publisher Site | Google Scholar
  63. G.-Y. Li, B. Fan, and Y.-Y. Jiao, “Rapamycin attenuates visible light-induced injury in retinal photoreceptor cells via inhibiting endoplasmic reticulum stress,” Brain Research, vol. 1563, pp. 1–12, 2014. View at: Publisher Site | Google Scholar
  64. H. Liu, J. Qian, F. Wang et al., “Expression of two endoplasmic reticulum stress markers, GRP78 and GADD153, in rat retinal detachment model and its implication,” Eye, vol. 24, no. 1, pp. 137–144, 2010. View at: Publisher Site | Google Scholar
  65. J. Feng, X. Chen, X. Sun, F. Wang, and X. Sun, “Expression of endoplasmic reticulum stress markers GRP78 and CHOP induced by oxidative stress in blue light-mediated damage of A2E-containing retinal pigment epithelium cells,” Ophthalmic Research, vol. 52, pp. 224–233, 2014. View at: Publisher Site | Google Scholar
  66. J. Li, J. J. Wang, Q. Yu, M. Wang, and S. X. Zhang, “Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy,” FEBS Letters, vol. 583, no. 9, pp. 1521–1527, 2009. View at: Publisher Site | Google Scholar
  67. T. McLaughlin, M. Falkowski, J. J. Wang, and S. X. Zhang, “Molecular Chaperone ERp29: A Potential Target for Cellular Protection in Retinal and Neurodegenerative Diseases,” in Retinal Degenerative Diseases, vol. 1074 of Advances in Experimental Medicine and Biology, pp. 421–427, Springer International Publishing, Cham, 2018. View at: Publisher Site | Google Scholar
  68. C. Huang, J. J. Wang, G. Jing et al., “Erp29 attenuates cigarette smoke extract–induced endoplasmic reticulum stress and mitigates tight junction damage in retinal pigment epithelial cells,” Investigative Ophthalmology & Visual Science, vol. 56, no. 11, pp. 6196–6207, 2015. View at: Publisher Site | Google Scholar
  69. J. Gao, Y. Zhang, L. Wang et al., “Endoplasmic reticulum protein 29 is involved in endoplasmic reticulum stress in islet beta cells,” Molecular Medicine Reports, vol. 13, no. 1, pp. 398–402, 2016. View at: Publisher Site | Google Scholar
  70. E. Sargsyan, M. Baryshev, M. Backlund, A. Sharipo, and S. Mkrtchian, “Genomic organization and promoter characterization of the gene encoding a putative endoplasmic reticulum chaperone, ERp29,” Gene, vol. 285, no. 1-2, pp. 127–139, 2002. View at: Publisher Site | Google Scholar
  71. D. Gao, I. F. Bambang, T. C. Putti, Y. K. Lee, D. R. Richardson, and D. Zhang, “ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58 IPK,” Laboratory Investigation, vol. 92, no. 2, pp. 200–213, 2012. View at: Publisher Site | Google Scholar
  72. S. Chen and D. Zhang, “Friend or foe: Endoplasmic reticulum protein 29 (ERp29) in epithelial cancer,” FEBS Open Bio, vol. 5, pp. 91–98, 2015. View at: Publisher Site | Google Scholar
  73. S. Park, H. Hwang, Y. Lee, K. You, K. Shin, and O. Kwon, “Expression of endoplasmic reticulum chaperone ERP29 in the injured spinal cord,” Korean Journal of Biological Sciences, vol. 7, no. 3, pp. 265–269, 2010. View at: Publisher Site | Google Scholar
  74. S. S. Cao and R. J. Kaufman, “Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease,” Antioxidants & Redox Signaling, vol. 21, no. 3, pp. 396–413, 2014. View at: Publisher Site | Google Scholar
  75. W. C. Chong, M. D. Shastri, and R. Eri, “Endoplasmic reticulum stress and oxidative stress: A vicious nexus implicated in bowel disease pathophysiology,” International Journal of Molecular Sciences, vol. 18, no. 4, 2017. View at: Google Scholar
  76. S. Patel, D. Sharma, K. Kalia, and V. Tiwari, “Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches,” Neuroscience & Biobehavioral Reviews, vol. 83, pp. 589–603, 2017. View at: Publisher Site | Google Scholar
  77. Giuseppina Amodio, Ornella Moltedo, Raffaella Faraonio, and Paolo Remondelli, “Targeting the Endoplasmic Reticulum Unfolded Protein Response to Counteract the Oxidative Stress-Induced Endothelial Dysfunction,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 4946289, 13 pages, 2018. View at: Publisher Site | Google Scholar
  78. A.-X. Liu, W.-H. He, L.-J. Yin et al., “Sustained endoplasmic reticulum stress as a cofactor of oxidative stress in decidual cells from patients with early pregnancy loss,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 3, pp. E493–E497, 2011. View at: Publisher Site | Google Scholar

Copyright © 2018 Minzhong Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1001 Views | 355 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.